Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.
about
Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohortPharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsAcute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort studyInterleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virusIL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infectionHepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study.Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.Dynamics of HCV RNA levels during acute hepatitis C virus infection.Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) studyPlasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infectionDanoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals.Characterization of the Interleukin-28B Gene rs12979860 C/T Polymorphism in Turkish Chronic Hepatitis C Patients and Healthy Individuals.The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C.Role of genetic polymorphisms in hepatitis C virus chronic infection.The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirinFactors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 studyInterferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patientsIL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associationsHepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 StudyResponse to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.Impaired hepatitis C virus (HCV)-specific interferon-γ responses in individuals with HIV who acquire HCV infection: correlation with CD4(+) T-cell counts.Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus.Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative.Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccinePlasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.The natural killer cell response to HCV infection.Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment.Role of interleukin-28B genetic polymorphisms in Korean patients with hepatitis C virus infection.Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision MakingHepatobiliary quiz-3 (2012)
P2860
Q28477975-EA56C266-114B-4620-83C9-DAEB55DC4C60Q30365599-FDF8ADA1-4F1D-48DC-AE6B-2F1A84614E96Q33779801-98638AE2-7FBA-47AB-A830-318A0C081D72Q33807010-8F71E268-3CCC-4D1A-BAD9-FBBFBA5095F1Q33867243-9190113F-74DC-4109-A60B-EAF0A75FE58AQ34008754-371E9D63-6D3A-4B7D-B6CD-465C1C78DB7BQ34411907-98C988F5-9296-4364-A806-24EBD1F025F0Q34539324-38899E47-3F3A-4550-9820-F8924AE0716EQ34546135-63B51B51-DB9D-4832-8174-D8D40FCEAA18Q34714349-F98F8298-DB1B-4131-9474-D85202A8E502Q34771346-290D3542-76B3-4233-B921-CC8720AB81B6Q34785317-5053CCB4-E0B1-42E1-AAC7-C0D74CBE38F0Q35053399-EE853D83-9A67-4601-8CA7-F7982A0784BEQ35065912-78E34A5A-155A-455F-AA9D-BF5BF324FF2EQ35083980-903C9AAA-BB5F-4E68-A567-C04666D6CFB1Q35249648-15F3D2BD-43AD-47A1-9EB6-4CC9D5D2F158Q35381792-3DE70042-0F9B-463D-9198-6B97D029AC1AQ35609162-8443C3B6-265D-41B7-8EBA-50E9F865612BQ35764210-5BEAEBAF-1035-44F5-A057-35D9C2B53268Q35779058-71681E8A-A15D-412E-8010-DBCC70F668F7Q35812034-779A2A1B-FA95-4BD3-BECD-2B2078040509Q35832850-27FBE4A9-5632-4DA8-86F8-CB5A007D7C5EQ35925546-2398C750-2914-4DB7-8FC6-4181A9DDF8C7Q35930570-9285DA03-B32F-41F3-9B3E-B768DC110B87Q36013021-6B171540-9DC7-42FC-90CA-7D3A51F710E5Q36148971-40B47621-4A13-4432-818D-8449187EE670Q36200292-A3833FD7-2067-487C-9D03-5CAF8A46F51CQ36224697-29D62A99-5A61-44BD-B3BD-609A39E6DEE4Q36330949-1DC00E65-3B77-4865-B11E-E9DB708E6968Q36478562-371AF06D-305B-4C1A-87AF-D019EFA7AA55Q36670894-CE2432EE-8B69-4DCB-B2C6-F4B843D5BD51Q36717008-E9CA5B91-F689-4443-AA72-1548EDF8FBFEQ36874661-42AECBC5-809B-4853-893D-C35E06466DB2Q37130266-6342EC3C-12FC-4D41-B039-4449284FA489Q37255644-87EB598F-A80F-4A22-A82C-5C3350703F4FQ37279158-7F436E8F-74E5-4944-9945-BA99427A0BD9Q37292899-E19B7F93-6F25-4A4A-8CFE-CAF4EF6BC2DAQ37564055-A88288CE-ADE4-436D-9801-1B1001F7E930Q37613481-060B8185-AEB9-467F-8BD7-B858D855B142Q37613918-246A372D-7CBF-4A14-981A-A57F45AA6D93
P2860
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Potential role for interleukin ...... t hepatitis C virus infection.
@ast
Potential role for interleukin ...... t hepatitis C virus infection.
@en
Potential role for interleukin ...... t hepatitis C virus infection.
@nl
type
label
Potential role for interleukin ...... t hepatitis C virus infection.
@ast
Potential role for interleukin ...... t hepatitis C virus infection.
@en
Potential role for interleukin ...... t hepatitis C virus infection.
@nl
prefLabel
Potential role for interleukin ...... t hepatitis C virus infection.
@ast
Potential role for interleukin ...... t hepatitis C virus infection.
@en
Potential role for interleukin ...... t hepatitis C virus infection.
@nl
P2093
P2860
P50
P356
P1433
P1476
Potential role for interleukin ...... t hepatitis C virus infection.
@en
P2093
ATAHC Study Group
Barbara Yeung
David Booth
Gail V Matthews
Gregory J Dore
Jacob George
Jason Grebely
John M Kaldor
Kathy Petoumenos
Margaret Hellard
P2860
P304
P356
10.1002/HEP.23850
P407
P577
2010-10-01T00:00:00Z